HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

bleselumab

an anti-CD40 antibody; in phase I clinical trials (2013)

Also Known As:

ASKP-1240; ASKP1240

Networked: 3 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Anil Kumar, Mysore S: 1 article (05/2018)
2.	Papp, Kim: 1 article (05/2018)
3.	Schwabe, Christian: 1 article (05/2018)
4.	Tainaka, Ryo: 1 article (05/2018)
5.	Valluri, Udaya: 1 article (05/2018)
6.	Wang, Xuegong: 1 article (05/2018)
7.	Zhu, Tong: 1 article (05/2018)
8.	Goto, M: 1 article (06/2014)
9.	Ishihara, T: 1 article (06/2014)
10.	Ishikawa, T: 1 article (06/2014)

Related Diseases

1.	Psoriasis (Pustulosis Palmaris et Plantaris) 05/01/2018 - "Patients with moderate-to-severe psoriasis were randomized on day 1 to receive bleselumab or placebo on days 1, 15 and 29 in a dose-escalation of bleselumab at 0.1, 0.3, 1.0 or 3.0 mg/kg. The safety-analysis set (SAF) and full-analysis set (FAS) included all patients who received bleselumab or placebo, and the PK-analysis set (PKAS) included patients in the SAF with ≥1 quantifiable serum bleselumab concentration. " 05/01/2018 - "Randomized, controlled study of bleselumab (ASKP1240) pharmacokinetics and safety in patients with moderate-to-severe plaque psoriasis."
2.	Hypersensitivity (Allergy) 06/01/2014 - "In vivo administration of ASKP1240 (1 or 10 mg/kg, intravenously) to cynomolgus monkeys, weekly for 3 weeks, significantly attenuated both delayed-type hypersensitivity and specific antibody formation evoked by tetanus toxoid. "
3.	Autoimmune Diseases (Autoimmune Disease) 06/01/2014 - "Thus, these results suggest that ASKP1240 is immunosuppressive but not prothromboembolic, and as such appears to be a promising therapeutic candidate for the management of solid organ transplant rejection and autoimmune diseases therapy."
4.	Cytokine Release Syndrome 04/01/2013 - "CD40 receptor occupancy by ASKP1240, which was dose-dependent, reached a maximum at doses above 0.01 mg/kg. ASKP1240 was well tolerated, with no evidence of cytokine release syndrome or thromboembolic events. "

Related Drugs and Biologics

1.	bleselumab
2.	Tetanus Toxoid (Vaccine, Tetanus)
3.	Syntex adjuvant formulation

Related Therapies and Procedures

1.	Therapeutics